Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation

Liver Transplantation

Volumn 14, Issue 2, 2008, Pages 245-251

  Alexander, Jacob ^a   Lord, James D ^a   Yeh, Matthew M ^b   Cuevas, Carlos ^a   Bakthavatsalam, Ramasamy ^a   Kowdley, Kris V ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGRAFT; ANTIGEN DETECTION; ARTICLE; BILE DUCT DILATATION; CHOLANGIOGRAPHY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GRAFT FAILURE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; STENT; TREATMENT RESPONSE;

ADULT; AGED; CHOLANGIOGRAPHY; CHOLANGITIS, SCLEROSING; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GRAFT REJECTION; HLA-DR ANTIGENS; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RECURRENCE; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 39449138743     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21394     Document Type: Article

References (31)

1. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006;26:22-30.
2. Solano E, Khakhar A, Bloch M, Quan D, McAlister V, Ghent C, et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 2003;35:2431-2434.
3. Bjoro K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2006;26:69-79.
4. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886-897.
5. Kubota T, Thomson A, Clouston AD, Nakazawa Y, Steadman C, Kerlin P, et al. Clinicopathologic findings of recurrent primary sclerosing cholangitis after orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 1999;6: 377-381.
6. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, Neuberger J. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002;360: 1943-1944.
7. Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997;225:472-481.
8. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 1998;66: 1300-1306.
9. Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003;34:1127-1136.
10. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999;29:1050-1056.
11. Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J Clin Gastroenterol 2003;37:344-347.
12. Brandsaeter B, Schrumpf E, Bentdal O, Brabrand K, Smith HJ, Abildgaard A, et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005;11:1361-1369.
13. Neuberger J. Recurrence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Liver Transpl Surg 1995;1(Suppl 1):109-115.
14. Abu-Elmagd K, Demetris AJ, Rakela J, Kang Y, Martin D, Dvorchik I, et al. Recurrence of primary sclerosing cholangitis (PSC) after hepatic transplantation (HTx): single center experience with 380 grafts. Transplantation 1999;67: S236.
15. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003;9:727-732.
16. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-1127.
17. Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung J, Geller SA, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
18. Ontanon J, Muro M, Garcia-Alonso AM, Minguela A, Torio A, Bermejo J, et al. Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. Transplantation 1998;65:1047-1053.
19. Rai RM, Boitnott J, Klein AS, Thuluvath PJ. Features of recurrent primary sclerosing cholangitis in two consecutive liver allografts after liver transplantation. J Clin Gastroenterol 2001;32:151-154.
20. Baan CC, van der Mast BJ, Klepper M, Mol WM, Peeters AM, Korevaar SS, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005;80:110-117.
21. Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, Merino R, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006;82:550-557.
22. Oertel M, Sack U, Kohlhaw K, Lehmann I, Emmrich F, Berr F, et al. Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte sub-populations after liver transplantation: results of a long-term study. Transpl Int 2002;15:463-471.
23. Donaldson PT, Farrant JM, Wilkinson ML, Hayllar K, Portmann BC, Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology 1991;13:129-133.
24. Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens 1999;53:459-469.
25. Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, et al. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol 2001; 36:886-890.
26. Underhill J, Donaldson P, Bray G, Doherty D, Portmann B, Williams R. Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype. Hepatology 1992;16:1404-1408.
27. Smerdel A, Ploski R, Flato B, Musiej-Nowakowska E, Thorsby E, Forre O. Juvenile idiopathic arthritis (JIA) is primarily associated with HLA-DR8 but not DQ4 on the DR8-DQ4 haplotype. Ann Rheum Dis 2002;61:354-357.
28. Nepom BS, Malhotra U, Schwarz DA, Nettles JW, Schaller JG, Concannon P. HLA and T cell receptor polymorphisms in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1260-1267.
29. Burak KW, Urbanski SJ, Swain MG. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases. Dig Dis Sci 2001;46:2043-2047.
30. Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56: 237-242.
31. Cullen SN, Chapman RW. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 2005;21:933-948.